Siroz ve Kronik Karaciğer Hastalığında Özel Hasta Eğitimi
Özet
Siroz ve kronik karaciğer hastalıkları; ilerleyici doğaları, çok sayıda potansiyel komplikasyonu ve farmakolojik-diyet kısıtlamalarının karmaşıklığı nedeniyle hastanın aktif katılımını zorunlu kılan hastalık gruplarıdır. Hasta eğitiminin yetersiz olduğu durumlarda asit kontrolsüzlüğü, hepatik ensefalopati atakları, varis kanamaları ve spontan bakteriyel peritonit (SBP) gibi yaşamı tehdit eden komplikasyonların önemli bir bölümü önlenebilir niteliktedir. Bu bölümde siroz tanısının hastaya iletilmesi, kompanse ve dekompanse evre farkı, komplikasyona özgü eğitim içerikleri (asit, hepatik ensefalopati, varis kanaması, SBP, hepatorenal sendrom), beslenme eğitimi, ilaç güvenliği ve NSAİİ yasağı, hepatoselüler karsinom (HCC) taramasının önemi, etiyolojiye özgü eğitim, karaciğer transplantasyonu sürecine hazırlık ve aile eğitimi ele alınır. Tüm öneriler EASL, AASLD, Baveno VII, ESPEN ve ACG kılavuzları ışığında hazırlanmıştır.
Cirrhosis and chronic liver disease require active patient participation due to their progressive nature, multiple potential complications and the complexity of pharmacological and dietary restrictions. In settings where patient education is inadequate, a significant proportion of life-threatening complications — including uncontrolled ascites, hepatic encephalopathy episodes, variceal bleeding and spontaneous bacterial peritonitis (SBP) — are potentially preventable. This chapter covers the communication of a cirrhosis diagnosis, the difference between compensated and decompensated disease, complication-specific education (ascites, hepatic encephalopathy, variceal bleeding, SBP, hepatorenal syndrome), nutritional education, drug safety and NSAID prohibition, the importance of hepatocellular carcinoma (HCC) surveillance, aetiology-specific education, preparation for liver transplantation and family education, all in accordance with EASL, AASLD, Baveno VII, ESPEN and ACG guidelines
Referanslar
European Association for the Study of the Liver. EASL Clini¬cal Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Gui¬dance on risk stratification and management of portal hyper¬tension and varices in cirrhosis. Hepatology. 2024;79(5):1180- 1211.
de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974.
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evalu¬ation, and Management of Ascites, Spontaneous Bacterial Pe¬ritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology. 2021;74(2):1014-1048.
European Association for the Study of the Liver. EASL Clini¬cal Practice Guidelines on the management of hepatic encep¬halopathy. J Hepatol. 2022;77(3):807-824.
Reiberger T, Mandorfer M. Beta adrenergic blockade and de-compensated cirrhosis. J Hepatol. 2017;66(4):849-859.
Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38(2):485- 521.
European Association for the Study of the Liver. EASL Clini¬cal Practice Guidelines: Management of hepatocellular carci¬noma. J Hepatol. 2018;69(1):182-236.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hy-pertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management — 2016 practice guidance by the AASLD. Hepatology. 2017;65(1):310-335.
Tandon P, Montano-Loza AJ, Lai JC, et al. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75(Suppl 1):S147-S162.
Marchesini G, Bianchi G, Merli M, et al. Nutritional supp-lementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124(7):1792-1801.
Kamath PS, Kim WR. The Model for End-Stage Liver Disease (MELD). Hepatology. 2007;45(3):797-805.
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681-693.
Simonetto DA, Gines P, Kamath PS. Hepatorenal syndro¬me: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687.
European Association for the Study of the Liver (EASL), EASD, EASO. EASL-EASD-EASO Clinical Practice Guideli¬nes on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492- 542.
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the AASLD and EASL. Hepatology. 2014;60(2):715-735.
Montagnese S, Rautou PE, Romero-Gómez M, et al. How patients with cirrhosis understand hepatic encephalopathy. J Hepatol. 2021;74(3):593-602.
Kalaitzakis E, Björnsson E. Inadequate education and lack of information in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2007;19(1):62-68.
Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroente¬rol. 2014;20(18):5442-5460.
